Global Anti-Obesity Drugs Market Trends and Drivers, Restraints, and Opportunities 2017-2023

  • Product Code:
  • Published Date:
    14 May 2019
  • Region:
  • Pages:
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

Anti-obesity Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Globally, obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults, who were 18 years and older were overweight. Of these over 650 million were obese. An obese individual is at a higher risk of developing chronic diseases such as breast cancer, endometrial cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders.
Anti-obesity drugs help in reducing body mass either by dipping the hunger or increasing the consumption of calories. The increasing prevalence of obesity globally is a major factor driving the market. It is principally because of wrong eating habits and swiftly varying regime of people. The increasing ingestion of unhealthy food along with the lack of exercises is intensifying the incidence rate of obesity globally.
Basic activities like reducing the intake of unhealthy diet and inculcating workout are not highly effective, and the medical devices like intragastric balloon and bariatric surgery are highly expensive and has high complications. This shows that there is a wide gap for the treatment of obesity. This unmet need is driving the market for anti-obesity drugs market.
Ill effects, such as the risk of mental illness, suicidal symptoms, stroke, are natively impacting the anti-obesity drugs market. Many drugs that were approved previously were withdrawn because of their side effects. Due to these factors healthcare specialists have an undesirable insight and do not recommend them to their clients.
Market Analysis: The Global Anti-Obesity Drugs Market is estimated to witness a CAGR of 20.9% during the forecast period 2017–2023. The market is analyzed based on three segments, namely top FDA approved drugs, types of anti-obesity drugs, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the leading region for the anti-obesity drugs market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. India and China are set to be the most attractive destinations due to the large untapped market.
Types Analysis: The top FDA approved anti-obesity drugs are Xenical, Saxenda, Contrave, Belviq, and Qsymia. Xenical was the largest selling drug in the market until 2012, but saw a dip in its revenue over the years. However, recently approved Saxenda by Novo Nordisk is gaining large interest among obese people and is growing at a fast growth rate.
Key Players: F. Hoffmann La Roche, GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd. are the key players in the market. Boehringer Ingelheim, Merck & Co, Nova Nordisk, Pfizer, Rhythm Pharmaceuticals, Zafgan, and Takeda Pharmaceuticals are the other prominent vendors.
Competitive Analysis: Novo Nordisk, an innovator of drugs in the obesity market, launched Saxenda in all the major markets with a higher dose of glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, which was first launched for type 2 diabetes as Victoza. Dual therapy for obesity and type 2 diabetes is the latest trend in the market. Therefore, big pharmaceutical companies, such as AstraZeneca, J&J, and Sanofi, are adopting low-risk strategy of using diabetes drugs to treat the obesity related problem. This helps the diabetes market players to enter the obesity market. J&J is intended to enter the market for prescription anti-oobesity drugs without further investing in the development of novel molecules.
Benefits: The report provides complete details about the usage and adoption rate of anti-obesity drugs during the forecast period and the various regions. With that, the key stakeholders can know about the major trends, drivers, and investments, along with the details of the commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding business in this market.
Key Stakeholders:

Table of Contents
1 Industry Outlook 9
1.1 Industry Overview 9
1.2 Industry Trends 9
2 Report Outline 10
2.1 Report Scope 10
2.2 Report Summary 10
2.3 Research Methodology 11
2.4 Report Assumptions 12
3 Market Snapshot 12
3.1 Market Definition – Infoholic Research 12
3.2 Total Addressable Market 12
3.3 Segmented Addressable Market 13
3.4 Related Markets 14
3.4.1 Diabetes Drugs 14
3.4.2 Active Pharmaceutical Ingredients 15
3.4.3 Intragastric Balloon 15
3.4.4 Oncology (Cancer) Drugs 16
4 Market Outlook 16
4.1 Overview 16
4.2 Market Segmentation 17
4.3 Porter 5(Five) Forces 18
4.4 PEST Analysis 19
5 Market Characteristics 20
5.1 Market Evolution 20
5.2 Market Dynamics 21
5.2.1 Drivers 22 High prevalence of obesity 22 Unhealthy lifestyle 22 Chronic nature of obesity 23
5.2.2 Opportunities 23 Growing awareness of fitness 23 Large untapped market 23
5.2.3 Restraints 23 Side effects related to anti-obesity drugs 23 Availability of alternative treatment options 24
5.3 DRO – Impact Analysis 24
5.4 Key Stakeholders 25
6 Drug Details: Market Size and Analysis 26
6.1 Overview 26
6.2 Orlistat 27
6.3 Phentermine/Topiramate ER 27
6.4 Lorcaserin 28
6.5 Naltrexone SR/Bupropion SR 28
6.6 Liraglutide 3.0 mg 28
7 Types: Market Size and Analysis 29
7.1 Overview 29
7.2 Prescription Drugs (Rx) 29
7.3 OTC Drugs 30
8 Regions: Market Size and Analysis 31
8.1 Overview 31
8.2 North America 33
8.2.1 Overview 33
8.2.2 US 34
8.2.3 Canada 34
8.2.4 Mexico 34
8.3 Europe 35
8.3.1 Overview 35
8.3.2 UK 36
8.3.3 Germany 36
8.4 Asia Pacific 37
8.4.1 Overview 37
8.4.2 India 37
8.4.3 China 38
8.4.4 Australia 38
8.5 Rest of the World 38
8.5.1 Overview 38
8.5.2 Brazil 39
8.5.3 Africa 39
8.5.4 Middle East 39
9 Competitive Landscape 40
10 Vendors Profiles 42
10.1 F. Hoffmann-La Roche Ltd. 42
10.1.1 Overview 42
10.1.2 Business Units 45
10.1.3 Geographic Revenue 46
10.1.4 Business Focus 46
10.1.5 SWOT Analysis 47
10.1.6 Business Strategies 47
10.2 GlaxoSmithKline plc 48
10.2.1 Overview 48
10.2.2 Business Units 50
10.2.3 Geographic Revenue 51
10.2.4 Business Focus 52
10.2.5 SWOT Analysis 52
10.2.6 Business Strategies 53
10.3 Vivus, Inc. 53
10.3.1 Overview 53
10.3.2 Business Focus 55
10.3.3 SWOT Analysis 55
10.3.4 Business Strategies 56
10.4 Orexigen Therapeutics, Inc. 57
10.4.1 Overview 57
10.4.2 Business Focus 58
10.4.3 SWOT Analysis 59
10.4.4 Business Strategies 59
10.5 Eisai Co., Ltd. 59
10.5.1 Overview 59
10.5.2 Geographic Revenue 61
10.5.3 Business Focus 61
10.5.4 SWOT Analysis 61
10.5.5 Business Strategies 62
11 Companies to Watch for 62
11.1 Pfizer, Inc. 63
11.1.1 Overview 63
11.1.2 Highlights 64
11.2 Nova Nordisk A/S 64
11.2.1 Overview 64
11.2.2 Highlights 65
11.3 Boehringer Ingelheim GmbH 65
11.3.1 Overview 65
11.4 Rhythm Pharmaceuticals, Inc. 66
11.4.1 Overview 66
11.5 Zafgen, Inc. 67
11.5.1 Overview 67
11.6 Norgine B.V. 67
11.6.1 Overview 67
11.7 Merck & Co. 68
11.7.1 Overview 68
11.7.2 Highlights 69
11.8 Takeda Pharmaceutical Co., Ltd. 69
11.8.1 Overview 69
Annexure 70
Abbreviations 70

Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
F. Hoffmann La Roche, GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd. are the key players in the market. Boehringer Ingelheim, Merck & Co, Nova Nordisk, Pfizer, Rhythm Pharmaceuticals, Zafgan, and Takeda Pharmaceuticals are the other prominent vendors
Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports